BioNTech Just Lost the Scientist Who Saved the World
The scientist who launched Project Lightspeed and delivered the world's first mRNA COVID vaccine is leaving BioNTech to start something new. His replacement? A dealmaking CEO who quadrupled Sobi's revenue in nine years.
In January 2020, Uğur Şahin read a medical journal article about a mysterious respiratory virus spreading through Wuhan, China. Most people skimmed past it. Şahin called an emergency board meeting.
Within weeks, BioNTech had shelved its cancer research and launched Project Lightspeed. Ten months later, the company delivered the first authorized mRNA vaccine against COVID-19. It was the fastest vaccine development in human history, built on two decades of mRNA work that almost nobody had believed in.
Now the man who made that call is walking away.
The End of the Founder Era
BioNTech announced that Şahin will step down as CEO, with Guido Oelkers, the current chief executive of Swedish rare disease drugmaker Sobi, appointed as his successor. Oelkers will take office by February 1, 2027, giving the company roughly six months for a structured handover.
Şahin isn't retiring to a vineyard. He and his wife, Özlem Türeci (BioNTech's chief medical officer), are leaving together to launch a brand-new biotech company focused on next-generation mRNA medicines. BioNTech will grant certain rights to its mRNA technology to the new venture and take a minority equity stake, keeping the scientific family tree intact.
Think of it like a restaurant founder handing the keys to a professional operator so they can go open a experimental pop-up kitchen. The original restaurant keeps running; the chef just wants to cook something new.
Who Is Guido Oelkers?
If Şahin was the visionary scientist, Oelkers is the business-scaling machine. The guy has been CEO of four different companies across pharma and medical technology, and his track record at Sobi tells you everything you need to know.
When Oelkers took over Sobi in 2017, revenues sat around SEK 6.5 billion. By 2024, they had climbed past SEK 26 billion: more than a fourfold increase. He did it through a string of disciplined acquisitions, spending $1.5 billion on U.S. rights to the RSV drug Synagis, nearly $915 million on Dova Pharmaceuticals, and about $1.7 billion on CTI BioPharma. Each deal added a new rare disease asset to Sobi's portfolio.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Analysts describe him as a "results-oriented strategist and entrepreneur" who transformed a mid-sized European specialty company into a global rare disease player. BioNTech's supervisory board called him a "seasoned CEO and strategic leader" with strength in managing complex product portfolios and global operations, particularly in the U.S. market.
That U.S. expertise matters enormously. BioNTech's future depends on launching cancer drugs in the world's biggest pharmaceutical market, and the company needs someone who knows how to do it at scale.
Why BioNTech Needs a Different Kind of Leader
BioNTech's identity crisis has been hiding in plain sight for years. The company became a household name because of COVID vaccines, but COVID revenue has been drying up. The real bet, the one that will determine whether BioNTech becomes a lasting pharmaceutical power or a pandemic-era footnote, is oncology.
And the pipeline they've assembled is genuinely massive. BioNTech now has over 25 Phase 2/3 oncology trials running across three core approaches: next-generation immunomodulators (drugs that tune the immune system), antibody-drug conjugates or ADCs (targeted missiles that deliver chemotherapy directly to cancer cells), and mRNA cancer immunotherapies (vaccines trained against each patient's specific tumor).
At the start of 2025, the company had just two Phase 3 oncology trials. By the end of 2026, they expect to be running roughly 15 Phase 3 programs, with seven late-stage data readouts that could support regulatory approvals. That's approaching the Phase 3 scale of Roche, one of the world's biggest oncology companies.
Building a pipeline is a scientist's job. Turning a pipeline into a commercial empire requires a different skillset entirely: supply chains, sales forces, market access, capital allocation. That's why you hire someone like Oelkers.
The Drugs to Watch
BioNTech's oncology strategy centers on a few headline programs that could start generating approval decisions in the next couple of years.
Pumitamig is their lead immunomodulator, currently in a Phase 2/3 trial for first-line non-small cell lung cancer. Early dose-optimization data showed encouraging anti-tumor activity when combined with chemotherapy, and the pivotal Phase 3 portion is comparing it head-to-head against Merck's blockbuster Keytruda (pembrolizumab) plus chemo. Beating the king of cancer immunotherapy would be a seismic event.
Gotistobart, an anti-CTLA-4 antibody, is in Phase 3 for squamous lung cancer and showing intriguing overall survival data in platinum-resistant ovarian cancer, potentially offering patients a chemotherapy-free option.
Trastuzumab pamirtecan (T-Pam), a HER2-targeting ADC, has late-stage trials running in both breast and endometrial cancers. And BNT113, an mRNA cancer vaccine, is in Phase 3 for HPV-driven head and neck cancer.
The company is also running over 10 "novel-novel" combination studies, mixing these different drug types together. It's an ambitious, swing-for-the-fences strategy. The question is whether the data will cooperate.
Wall Street's Early Verdict
BioNTech shares fell sharply on the news of the CEO transition. Automated filing analysis tagged the announcement as "neutral" in both impact and sentiment, which in financial-speak means: this was expected and orderly, not a crisis.
The broader interpretation from industry analysts is that this leadership change is a governance milestone, not a thesis change. BioNTech's stock will ultimately be driven by clinical data readouts over the next 12 to 18 months, not by who's sitting in the corner office. Oelkers' job is to make sure the company is ready to commercialize whatever those trials deliver.
What Happens to Sobi?
Oelkers' departure creates a second succession story. Sobi's board has started a formal search for a new CEO, but hasn't named a candidate yet. The incoming leader will inherit an unfinished growth plan targeting roughly SEK 55 billion in revenue by 2030, nearly double current levels, dependent on six major product launches and continued dealmaking.
Finding someone who can fill the shoes of a CEO who quadrupled your revenue in nine years is, to put it mildly, a tall order.
The Bigger Picture
Şahin and Türeci's departure marks the end of something rare in biotech: a founder-led company that went from obscure cancer research lab to global pandemic hero and is now attempting to become a top-tier oncology powerhouse. Most biotechs never make it past one of those stages, let alone all three.
The fact that both founders are leaving to start another mRNA company, with BioNTech's blessing and technology rights, suggests they believe the best mRNA science is still ahead of them. BioNTech, meanwhile, is betting that its best commercial days are ahead, too; it just needs a different captain for that particular voyage.
Şahin built the ship. Oelkers is being asked to sail it into harbor. Whether the cargo holds up depends on the data coming in 2026 and 2027. For BioNTech investors, the real drama isn't in the C-suite. It's in the clinic.
5 min read
Two CNS Pharma Companies Just Stitched Themselves Together. Here's Why.
Supernus and Indivior are merging into a $2.2 billion CNS and addiction powerhouse, combining ADHD drugs with the dominant opioid treatment franchise. It's specialty pharma's latest bet that brain disorders and addiction belong under one roof.
